<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alector Inc — News on 6ix</title>
<link>https://6ix.com/company/alector-inc</link>
<description>Latest news and press releases for Alector Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alector-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835451c78dffbe2df0e26b9.webp</url>
<title>Alector Inc</title>
<link>https://6ix.com/company/alector-inc</link>
</image>
<item>
<title>Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis</title>
<link>https://6ix.com/company/alector-inc/news/alector-to-discontinue-phase-2-progress-ad-trial-of-nivisnebart-al101gsk4527226-in-early-alzheimers-disease-following-interim-futility-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-to-discontinue-phase-2-progress-ad-trial-of-nivisnebart-al101gsk4527226-in-early-alzheimers-disease-following-interim-futility-analysis</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer’s disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson’s disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SA</description>
</item>
<item>
<title>Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer’s Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease expected in</description>
</item>
<item>
<title>Alector to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/alector-inc/news/alector-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer</title>
<link>https://6ix.com/company/alector-inc/news/alector-appoints-neil-berkley-chief-financial-officer-and-chief-business-officer-2025</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-appoints-neil-berkley-chief-financial-officer-and-chief-business-officer-2025</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Alector to Participate in the Bank of America CNS Therapeutics Conference</title>
<link>https://6ix.com/company/alector-inc/news/alector-participate-bank-america-cns-therapeutics-conference-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-participate-bank-america-cns-therapeutics-conference-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Alector Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its</description>
</item>
<item>
<title>Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-announces-topline-results-latozinemab-phase-3-trial-individuals</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-announces-topline-results-latozinemab-phase-3-trial-individuals</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs</title>
<link>https://6ix.com/company/alector-inc/news/alector-host-virtual-research-and-development-event-highlighting-pgrn-franchise-and</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-host-virtual-research-and-development-event-highlighting-pgrn-franchise-and</guid>
<pubDate>Tue, 16 Sep 2025 04:00:00 GMT</pubDate>
<description>--Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates-- SOUTH SAN FRANCISCO,</description>
</item>
<item>
<title>Alector to Participate in Upcoming Healthcare Conferences</title>
<link>https://6ix.com/company/alector-inc/news/alector-participate-upcoming-healthcare-conferences-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-participate-upcoming-healthcare-conferences-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing</description>
</item>
<item>
<title>Alector Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia</description>
</item>
<item>
<title>Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call</title>
<link>https://6ix.com/company/alector-inc/news/alector-host-second-quarter-and-mid-year-2025-earnings-conference-call-2025-07-31</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-host-second-quarter-and-mid-year-2025-earnings-conference-call-2025-07-31</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc.</description>
</item>
<item>
<title>Alector Provides Executive Leadership Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-provides-executive-leadership-update-2025-06-13</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-provides-executive-leadership-update-2025-06-13</guid>
<pubDate>Fri, 13 Jun 2025 04:00:00 GMT</pubDate>
<description>-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June</description>
</item>
<item>
<title>Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/alector-inc/news/alector-participate-goldman-sachs-46th-annual-global-healthcare-conference-2025-06-03</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-participate-goldman-sachs-46th-annual-global-healthcare-conference-2025-06-03</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing</description>
</item>
<item>
<title>Alector Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-reports-first-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-reports-first-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical</description>
</item>
<item>
<title>Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/alector-inc/news/alector-announces-completion-enrollment-progress-ad-phase-2-clinical-trial-al101</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-announces-completion-enrollment-progress-ad-phase-2-clinical-trial-al101</guid>
<pubDate>Thu, 17 Apr 2025 04:00:00 GMT</pubDate>
<description>--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of</description>
</item>
<item>
<title>Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides</guid>
<pubDate>Wed, 26 Feb 2025 05:00:00 GMT</pubDate>
<description>Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the</description>
</item>
<item>
<title>Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call</title>
<link>https://6ix.com/company/alector-inc/news/alector-host-fourth-quarter-and-full-year-2024-earnings-conference-call-2025-02-19</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-host-fourth-quarter-and-full-year-2024-earnings-conference-call-2025-02-19</guid>
<pubDate>Wed, 19 Feb 2025 05:00:00 GMT</pubDate>
<description>Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc.</description>
</item>
<item>
<title>Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025</title>
<link>https://6ix.com/company/alector-inc/news/alector-reports-recent-progress-and-outlines-strategic-priorities-2025-2025-01-13</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-reports-recent-progress-and-outlines-strategic-priorities-2025-2025-01-13</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s</description>
</item>
<item>
<title>Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update</title>
<link>https://6ix.com/company/alector-inc/news/alector-announces-results-al002-invoke-2-phase-2-trial-individuals-early-alzheimers</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-announces-results-al002-invoke-2-phase-2-trial-individuals-early-alzheimers</guid>
<pubDate>Mon, 25 Nov 2024 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel,</description>
</item>
<item>
<title>Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital</title>
<link>https://6ix.com/company/alector-inc/news/alector-secures-flexible-credit-facility-50-million-hercules-capital-2024-11-14</link>
<guid isPermaLink="true">https://6ix.com/company/alector-inc/news/alector-secures-flexible-credit-facility-50-million-hercules-capital-2024-11-14</guid>
<pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering</description>
</item>
</channel>
</rss>